IL138522A0 - Use of cabergoline in the treatment of restless legs syndrome - Google Patents

Use of cabergoline in the treatment of restless legs syndrome

Info

Publication number
IL138522A0
IL138522A0 IL13852299A IL13852299A IL138522A0 IL 138522 A0 IL138522 A0 IL 138522A0 IL 13852299 A IL13852299 A IL 13852299A IL 13852299 A IL13852299 A IL 13852299A IL 138522 A0 IL138522 A0 IL 138522A0
Authority
IL
Israel
Prior art keywords
cabergoline
treatment
restless legs
legs syndrome
syndrome
Prior art date
Application number
IL13852299A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of IL138522A0 publication Critical patent/IL138522A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13852299A 1998-03-27 1999-03-24 Use of cabergoline in the treatment of restless legs syndrome IL138522A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7963998P 1998-03-27 1998-03-27
PCT/US1999/004269 WO1999048484A2 (en) 1998-03-27 1999-03-24 Use of cabergoline in the treatment of restless legs syndrome

Publications (1)

Publication Number Publication Date
IL138522A0 true IL138522A0 (en) 2001-10-31

Family

ID=22151836

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13852299A IL138522A0 (en) 1998-03-27 1999-03-24 Use of cabergoline in the treatment of restless legs syndrome

Country Status (23)

Country Link
US (1) US6114326A (zh)
EP (1) EP1066038B1 (zh)
JP (1) JP2002507562A (zh)
KR (1) KR100597517B1 (zh)
CN (1) CN1303286A (zh)
AT (1) ATE313326T1 (zh)
AU (1) AU747751B2 (zh)
BR (1) BR9908953A (zh)
CA (1) CA2320204A1 (zh)
CZ (1) CZ297284B6 (zh)
DE (1) DE69929041T2 (zh)
DK (1) DK1066038T3 (zh)
EA (1) EA002554B1 (zh)
ES (1) ES2255255T3 (zh)
HU (1) HUP0101954A3 (zh)
IL (1) IL138522A0 (zh)
NO (1) NO20004799L (zh)
NZ (1) NZ507176A (zh)
PL (1) PL343593A1 (zh)
SK (1) SK13312000A3 (zh)
TR (1) TR200002759T2 (zh)
WO (1) WO1999048484A2 (zh)
ZA (1) ZA200004452B (zh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50070B (sr) 1997-12-22 2009-01-22 Euro-Celtique S.A., Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6477408B1 (en) * 2000-03-07 2002-11-05 Northwestern University Analysis of muscular activity in neonatal animals to screen for mutations and/or drugs that alter sleep and wake states
GB0007309D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
US6426713B1 (en) * 2000-07-05 2002-07-30 Cirrus Logic, Inc. Independent control of calibration registers in a multi channel A-D converter
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20020123503A1 (en) * 2000-12-21 2002-09-05 Malcolm Ross Cabergoline pharmaceutical compositions and methods of use thereof
WO2002078744A1 (fr) * 2001-03-30 2002-10-10 Toray Industries, Inc. Remedes contre la psychonevrose
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US20030134844A1 (en) * 2001-10-31 2003-07-17 Pfizer Inc. Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
US20030176822A1 (en) * 2002-03-12 2003-09-18 Morgenlander Joel C. Method of treating restless leg syndrome
DK2425824T5 (en) 2002-04-05 2018-02-12 Mundipharma As Pharmaceutical preparation containing oxycodone and naloxone
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
KR20050058468A (ko) 2002-08-30 2005-06-16 교와 핫꼬 고교 가부시끼가이샤 하지불안증후군 또는 관련 장애 치료용 아데노신 ａ2ａ 수용체 길항제
WO2005027850A2 (en) 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
KR20060030175A (ko) * 2004-10-05 2006-04-10 경북대학교 산학협력단 무정위성 운동 치료용 약학조성물
KR20090029856A (ko) * 2005-01-28 2009-03-23 유로-셀띠끄 소시에떼 아노님 알코올 저항성 제형
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
ES2684821T3 (es) * 2005-12-29 2018-10-04 Lexicon Pharmaceuticals, Inc. Derivados de aminoácidos multicíclicos y métodos de su uso
CN101442997B (zh) * 2006-04-03 2012-11-14 泰华制药工业有限公司 雷沙吉兰用于治疗多动腿综合征
WO2008046149A1 (en) * 2006-10-17 2008-04-24 Biologic Health Solutions Pty Ltd Herbal compositions for the prevention or treatment of restless leg syndrome
EP1952813A1 (en) * 2007-02-01 2008-08-06 Ferring International Center S.A. Medicament for the treatment of endometriosis
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
US7939665B2 (en) 2007-05-04 2011-05-10 Apotex Pharmachem Inc. Efficient process for the preparation of cabergoline and its intermediates
EP2067780A1 (en) * 2007-12-07 2009-06-10 Axxonis Pharma AG Ergoline derivatives as selective radical scavengers for neurons
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
ES2730678T3 (es) 2009-04-01 2019-11-12 Bial Portela & Ca Sa Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para fabricarlas
US8690933B2 (en) * 2009-08-31 2014-04-08 Brigham Young University System and method for treating symptoms of restless legs syndrome
AU2014295042B2 (en) 2013-07-23 2017-03-30 Mundipharma Pty Limited A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
PL232974B1 (pl) * 2015-12-09 2019-08-30 Ofta Spolka Z Ograniczona Odpowiedzialnoscia Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń
JP7159169B2 (ja) 2017-01-05 2022-10-24 ノクトリックス ヘルス インコーポレイテッド レストレスレッグス症候群または過活動神経治療
WO2021067751A1 (en) 2019-10-03 2021-04-08 Noctrix Health, Inc. Peripheral nerve stimulation for restless legs syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders

Also Published As

Publication number Publication date
HUP0101954A2 (hu) 2001-12-28
CZ297284B6 (cs) 2006-10-11
DE69929041D1 (de) 2006-01-26
EA002554B1 (ru) 2002-06-27
ES2255255T3 (es) 2006-06-16
AU3353199A (en) 1999-10-18
KR20010052222A (ko) 2001-06-25
JP2002507562A (ja) 2002-03-12
EP1066038B1 (en) 2005-12-21
CZ20003419A3 (cs) 2002-01-16
NZ507176A (en) 2003-09-26
KR100597517B1 (ko) 2006-07-10
PL343593A1 (en) 2001-08-27
NO20004799L (no) 2000-10-11
WO1999048484A3 (en) 1999-11-25
SK13312000A3 (sk) 2001-05-10
CN1303286A (zh) 2001-07-11
US6114326A (en) 2000-09-05
CA2320204A1 (en) 1999-09-30
BR9908953A (pt) 2000-12-05
AU747751B2 (en) 2002-05-23
TR200002759T2 (tr) 2001-02-21
WO1999048484A2 (en) 1999-09-30
ZA200004452B (en) 2002-02-27
ATE313326T1 (de) 2006-01-15
EA200000994A1 (ru) 2001-02-26
HUP0101954A3 (en) 2002-09-30
DE69929041T2 (de) 2006-07-20
DK1066038T3 (da) 2006-04-24
EP1066038A2 (en) 2001-01-10
NO20004799D0 (no) 2000-09-26

Similar Documents

Publication Publication Date Title
IL138522A0 (en) Use of cabergoline in the treatment of restless legs syndrome
YU15299A (sh) Farmaceutski sastavi
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
EP1112070A4 (en) NEW SUBSTITUTED TRIAZOLE COMPOUNDS
MXPA03003912A (es) Tratamientos nuevos para el sindrome de piernas inquietas.
AU1074902A (en) Kahalalide f
IL161501A0 (en) Methods of preventing and treating flavivirus infection in animals
HK1024408A1 (en) Use of pramipexole in the treatment of restless legs syndrome
ZA97188B (en) Disinfecting compositions and processes for disinfecting surfaces.
GB2323028B (en) Wheel and housing for table leg
EP0681787A3 (en) Use of an enzyme for the manufacture of an agent suitable for the treatment and / or prophylaxis of coccidiosis.
SI1187612T1 (en) Use of riluzole for the treatment of multiple sclerosis
HK1033876A1 (en) Use of nmda antagonists for treatment of irritablebowel syndrome.
BG104914A (en) Paroxetine maleate
IL139144A0 (en) Mycobacterial inhibitors
GEP20074097B (en) Use of specific dose of fondaparinux sodium for the treatment of acs
MXPA01010449A (es) Composicion y metodo util para el tratamiento del colico.
SI1066038T1 (sl) Uporaba kabergolina za zdravljenje sindroma nemirnih nog
CA98963S (en) Leg for table
GB9820727D0 (en) Table and or seat
TW357579U (en) Integrated one-piece desk and chair
ZA991945B (en) An article of office furniture.
TW381500U (en) Exerciser for waist, back, and the back part of legs
IT237515Y1 (it) Lettino trasportabile particolarmente studiato per massaggi e perfisioterapisti
TW380669U (en) Combination and fixing apparatus for conference table